NASDAQ: GOSS
Gossamer Bio Inc Stock

$10.72-0.51 (-4.54%)
Updated Nov 20, 2026
GOSS Price
$10.72
Fair Value Price
$9.45
Market Cap
$65.57M
52 Week Low
$8.29
52 Week High
$309.60
P/E
-0.3x
P/B
-0.53x
P/S
0.99x
PEG
N/A
Dividend Yield
N/A
Revenue
$78.42M
Earnings
-$125.07M
Gross Margin
100%
Operating Margin
-145.99%
Profit Margin
-159.5%
Debt to Equity
-1.52
Operating Cash Flow
-$156M
Beta
1.44
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A

GOSS Overview

Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary hypertension and pulmonary arterial hypertension in the United States. The company develops GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. The company was incorporated in 2015 and is headquartered in San Diego, California.

Zen Rating

Our proven quant model uses 115 proprietary factors, including AI, to determine GOSS's potential to beat the market

DSell
  • Stocks with a Zen Rating of Sell (D) had an average loss of -6.47% per year. Learn More

Zen Rating Component Grades

F
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.

Industry: Biotech

Industry Rating
F
GOSS
Ranked
#291 of 447

Top Ranked Stocks in Industry

View Top Biotech Stocks

Be the first to know about important GOSS news, forecast changes, insider trades & much more!

GOSS News

Overview

Due Diligence Score

–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how GOSS scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

GOSS ($10.72) is overvalued by 13.39% relative to our estimate of its Fair Value price of $9.45 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
GOSS ($10.72) is not significantly undervalued (13.39%) relative to our estimate of its Fair Value price of $9.45 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
GOSS is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more GOSS due diligence checks available for Premium users.

Valuation

GOSS fair value

Fair Value of GOSS stock based on Discounted Cash Flow (DCF)

Price
$10.72
Fair Value
$9.45
Overvalued by
13.39%
GOSS ($10.72) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
GOSS ($10.72) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
GOSS is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

GOSS price to earnings (PE)

For valuing profitable companies with steady earnings

Company
-0.3x
Industry
16.91x
Market
39.45x

GOSS price to book (PB)

For valuing companies that are loss-making or have lots of physical asset

Company
-0.53x
Industry
4.78x

GOSS's financial health

Profit margin

Revenue
$38.4M
Net Income
-$48.1M
Profit Margin
-125.1%
GOSS's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
GOSS's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials

Assets to liabilities

Assets
$64.3M
Liabilities
$187.1M
Debt to equity
-1.52
GOSS's short-term liabilities ($99.95M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
GOSS's long-term liabilities ($87.19M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
GOSS's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
GOSS's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$29.6M
Investing
$15.9M
Financing
$23.7M
GOSS's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

GOSS vs Biotech Stocks

TickerZen RatingMarket Cap1d %P/EP/B
GOSSD$65.57M-4.54%-0.30x-0.53x
TNYA–$65.42M-3.69%-0.60x1.20x
PMVPD$66.17M-33.13%-0.57x1.16x
PLYX–$66.30M-11.92%-7.39x8.71x
CRDFD$66.36M-4.16%-1.55x2.36x

Gossamer Bio Stock FAQ

What is Gossamer Bio's quote symbol?

(NASDAQ: GOSS) Gossamer Bio trades on the NASDAQ under the ticker symbol GOSS. Gossamer Bio stock quotes can also be displayed as NASDAQ: GOSS.

If you're new to stock investing, here's how to buy Gossamer Bio stock.

What is the 52 week high and low for Gossamer Bio (NASDAQ: GOSS)?

(NASDAQ: GOSS) Gossamer Bio's 52-week high was $309.60, and its 52-week low was $8.29. It is currently -96.54% from its 52-week high and 29.31% from its 52-week low.

How much is Gossamer Bio stock worth today?

(NASDAQ: GOSS) Gossamer Bio currently has 6,116,390 outstanding shares. With Gossamer Bio stock trading at $10.72 per share, the total value of Gossamer Bio stock (market capitalization) is $65.57M.

Gossamer Bio stock was originally listed at a price of $1,435.20 in Feb 8, 2019. If you had invested in Gossamer Bio stock at $1,435.20, your return over the last 7 years would have been -99.25%, for an annualized return of -50.32% (not including any dividends or dividend reinvestments).

How much is Gossamer Bio's stock price per share?

(NASDAQ: GOSS) Gossamer Bio stock price per share is $10.72 today (as of Nov 20, 2026).

What is Gossamer Bio's Market Cap?

(NASDAQ: GOSS) Gossamer Bio's market cap is $65.57M, as of Nov 21, 2026.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Gossamer Bio's market cap is calculated by multiplying GOSS's current stock price of $10.72 by GOSS's total outstanding shares of 6,116,390.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.